Pfizer and Blackstone agree up to $1.5 billion in development funding for monthly GLP-1 obesity candidate berobenatide
Pfizer and Blackstone Life Sciences have agreed a development co-funding arrangement of up to $1.5 billion for investigational once-monthly GLP-1 therapy berobenatide, sharing clinical development risk while Pfizer retains control of the programme.
Pfizer and Blackstone Life Sciences announced a strategic funding agreement on 11 November 2026 under which Blackstone-managed funds will provide up to $1.5 billion through 2028 toward the clinical development of berobenatide, an investigational once-monthly injectable GLP-1 receptor agonist being studied for chronic weight management and obesity-related conditions.
Under the arrangement, Blackstone may receive payments linked to US regulatory approval of monthly injectable berobenatide monotherapy and specified commercial sales milestones, while Pfizer retains the programme and its development responsibilities; the $1.5 billion represents a maximum development funding commitment rather than an acquisition price, guaranteed upfront consideration or regulatory approval.
Field | Content |
Article Type | Deals |
Pharmaceutical Company | Pfizer |
Funding Partner | Blackstone Life Sciences |
Funding Source | Blackstone-managed funds |
Deal Type | Strategic clinical development co-funding agreement |
Announcement Date | 11 November 2026 |
Agreement Status | Announced |
Funded Programme | Berobenatide |
Drug Development Status | Investigational |
Drug Class | GLP-1 receptor agonist |
Drug Modality | Injectable medicine |
Proposed Dosing Frequency | Once monthly |
Therapeutic Area | Obesity and metabolic disease |
Primary Development Focus | Chronic weight management |
Additional Development Focus | Obesity-related conditions |
Maximum Funding Commitment | Up to $1.5 billion |
Funding Period | Through 2028 |
Funding Purpose | Clinical development costs |
Funding Structure | Development co-funding with contingent return payments |
Funding Provider Consideration | Potential payments linked to regulatory and commercial milestones |
Regulatory Payment Trigger | US regulatory approval of monthly injectable berobenatide monotherapy |
Commercial Payment Triggers | Specified sales milestones |
Commercial Milestone Amounts | Not disclosed in supplied summary |
Programme Ownership | Retained by Pfizer |
Development Responsibilities | Retained by Pfizer |
Acquisition Involved | No |
Guaranteed Upfront Acquisition Payment | Not applicable |
Regulatory Approval Granted | No |
What Happened | Pfizer and Blackstone Life Sciences agreed to share funding and financial exposure associated with berobenatide clinical development. |
Why It Matters | The arrangement provides substantial external financing for an obesity programme while allowing Pfizer to retain ownership and development control. |
Strategic Significance | Illustrates a risk-sharing financing model for capital-intensive late-stage pharmaceutical development. |
Financial Clarification | The up to $1.5 billion figure is a funding commitment through 2028 rather than a purchase price or guaranteed cash payment to Pfizer. |
Regulatory Clarification | Berobenatide remains investigational and any future regulatory approval is contingent. |
Key Takeaway | Blackstone-managed funds may contribute up to $1.5 billion toward Pfizer's monthly GLP-1 development programme in return for contingent future payments. |
What to Watch | Clinical development milestones, efficacy and safety results, US regulatory progress, funding deployment and potential commercial milestone obligations. |
Primary Source | Blackstone |
Primary Source URL | https://www.blackstone.com/news/press/pfizer-and-blackstone-life-sciences-announce-strategic-funding-agreement-for-obesity-program/ |
Submitted Source | pharmaphorum |
Submitted Source URL | https://pharmaphorum.com/news/blackstone-buys-pfizers-glp-1-drug-development |
Relevant Date | 11 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments